These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 34865874

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E, López-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J.
    Vaccine; 2017 Jun 05; 35(25):3342-3346. PubMed ID: 28499554
    [Abstract] [Full Text] [Related]

  • 3. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
    Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L.
    J Natl Cancer Inst; 2013 Apr 03; 105(7):469-74. PubMed ID: 23486550
    [Abstract] [Full Text] [Related]

  • 4. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L.
    JAMA; 2014 Feb 12; 311(6):597-603. PubMed ID: 24519299
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S, Nygård M, Orumaa M, Hansen BT.
    Vaccine; 2023 Aug 23; 41(37):5469-5476. PubMed ID: 37516572
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.
    BMC Infect Dis; 2013 Feb 07; 13():75. PubMed ID: 23390964
    [Abstract] [Full Text] [Related]

  • 10. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V, Fett S, Tauscher M, Donnachie E, Schneider A, Klug SJ.
    BMC Cancer; 2022 Dec 09; 22(1):1293. PubMed ID: 36494790
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study.
    Baandrup L, Dehlendorff C, Kjaer SK.
    Clin Infect Dis; 2021 Nov 02; 73(9):e3220-e3226. PubMed ID: 33048118
    [Abstract] [Full Text] [Related]

  • 13. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.
    BMC Public Health; 2017 Feb 02; 17(1):152. PubMed ID: 28148228
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
    Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK.
    Lancet Infect Dis; 2011 Jan 01; 11(1):39-44. PubMed ID: 21067976
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 20. Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study.
    Judlin P, Jacquard AC, Carcopino X, Aubin F, Dahlab A, Mistretta F, Not D, Boelle PY, Aynaud O, Soubeyrand B.
    Sex Health; 2016 Feb 01; 13(1):49-54. PubMed ID: 26567557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.